Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027

Report Code: MD 3088 Jun, 2022, by marketsandmarkets.com

[294 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR. Market growth is driven by the global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

Infectious Disease Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020.

Since testing remains a crucial step in controlling the rapid spread of the disease, government organizations worldwide are supporting laboratories in streamlining COVID-19 testing procedures.The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing.

In line with this, regulatory authorities utilized methods to speed up the approval of COVID-19 diagnostic products. Moreover, major companies have undertaken strategic developments to introduce COVID-19 rapid tests and nullify the impact of COVID-19 on their operational capabilities, as diagnostic testing remains the backbone of the COVID-19 response, supporting containment efforts to mitigate the outbreak. Also, the severity of this crisis and increasing capacity issues associated with PCR-based testing accelerated the development of diagnostic solutions to meet the demands for mass testing. Major companies operating in this market scaled up their operations for testing and tracking COVID-19.

However, the COVID-19 pandemic has continued to show a strong decline in the world this year, with contaminations decelerating everywhere, leading to a decrease in the growth rate of the infectious disease diagnostics market. Since the start of the COVID-19 outbreak, the WHO has worked with countries and areas in the Western Pacific Region on public health measures to slow or stop the spread of the virus. Vaccines are an important tool, in combination with other measures, to protect people against COVID-19 and reduce widescale social disruption.

Market Dynamics

Driver: Global prevalence of infectious diseases

The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics; hence, it had a positive impact on this market.

Opportunity: Growing opportunities in growing economies

Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

Restraint: Unfavourable reimbursement scenario

Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.

In 2021, reagents, kits, and consumables segment accounted for the largest share of the infectious disease diagnostics market, by product & service”

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services, based on product & service. The reagents, kits, and consumables segment accounted for the largest share of this market in 2021. The recurrent usage of these products drives the market growth of this segment.

In 2021, immunodiagnostics segment accounted for the largest share in the market, by technology

The infectious disease diagnostics market is segmented into immunodiagnostics, PCR, clinical microbiology, INAAT, DNA sequencing & NGS, DNA microarray, and other technologies. In 2021, the immunodiagnostics segment accounted for the largest share. This can be attributed to the use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

North America is the largest regional market for the infectious disease diagnostics

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global infectious disease diagnostics market in 2021. The North American infectious disease diagnostics market's growth can be attributed to the high burden of infections, growing healthcare expenditure, implementation of favorable government initiatives, improved healthcare infrastructures and the easy accessibility to technologically advanced instruments.

Infectious Disease Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the infectious disease diagnostics market (2021- 2026)

  • Abbott Laboratories (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Siemens Healthineers AG (Germany)
  • bioMérieux SA (France)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD Billion)

Segments covered

Product & Service, type of testing, technology, disease type, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).

This report categorizes the infectious disease diagnostics market into the following segments and subsegments:

By Product

  • Reagents, Kits, and Consumables
  • Instruments
  • Software & Services

By Type of Testing

  • Laboratory Testing
  • POC Testing

By Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • PCR
  • INAAT
  • DNA Sequencing & NGS
  • DNA Microarray
  • Other technologies

By Disease Type

  • COVID-19
  • HIV
  • Hospital-acquired Infections
  • Hepatitis
  • Chlamydia Trachomatis
  • Neisseria Gonorrhea
  • HPV
  • Tuberculosis
  • Influenza
  • Syphilis
  • Mosquito-borne Diseases
  • Other Infectious Diseases

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Recent Developments

  • In November 2022, Roche Diagnostics Launched cobas 5800 system.
  • In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
  • In March 2020, Abbott Laboratories launched the ID NOW COVID-19 Test.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 32)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKETS SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
                    FIGURE 2 MARKETS COVERED - BY REGION
           1.3.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED
                    FIGURE 3 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Primary sources
                    2.2.1.2 Key data from primary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Breakdown of primary interviews
                    2.2.2.2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                    2.2.2.3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.2.2.4 MARKET SIZE ESTIMATION
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                               FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Growth forecast
                               FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
                    2.3.1.3 TOP-DOWN APPROACH
                    2.3.1.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
                               FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE
    2.6 STUDY ASSUMPTIONS
    2.7 LIMITATIONS
    2.8 GROWTH RATE ASSUMPTIONS
    2.9 RISK ASSESSMENT
           2.9.1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
           FIGURE 16 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
    4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
           FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 2022
    4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
           FIGURE 18 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027
           FIGURE 19 DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET

5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising technological advancements in infectious disease diagnostics
                    5.2.1.2 Shift in focus from centralized laboratories to decentralized POC testing
                    5.2.1.3 RESTRAINTS
                    5.2.1.4 Unfavorable reimbursement scenario
                    5.2.1.5 OPPORTUNITIES
           5.2.2 RESTRAINTS
                    5.2.2.1 CHALLENGES
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Operational barriers
           5.2.4 CHALLENGES
                    5.2.4.1 PRICING ANALYSIS
                    5.2.4.2 INDICATIVE PRICING MODEL ANALYSIS
           5.2.5 IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
    5.3 PRICING ANALYSIS
           5.3.1 INDICATIVE PRICING MODEL ANALYSIS
                    TABLE 1 INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022)
    5.4 PATENT ANALYSIS
           FIGURE 21 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS
           FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM MARKET MAP
           FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP
           5.7.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS
           TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 PESTLE ANALYSIS
    5.10 REGULATORY LANDSCAPE
           5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.10.2 NORTH AMERICA
                    5.10.2.1 EUROPE: CLASSIFICATION OF DEVICES
                    5.10.2.2 ASIA PACIFIC
           5.10.3 EUROPE
                     TABLE 7 EUROPE: CLASSIFICATION OF DEVICES
           5.10.4 ASIA PACIFIC
                    5.10.4.1 LATIN AMERICA
                    5.10.4.2 Brazil
                    5.10.4.3 Mexico
           5.10.5 LATIN AMERICA
                    5.10.5.1 AFRICA
                    5.10.5.2 TRADE ANALYSIS
           5.10.6 MIDDLE EAST
           5.10.7 AFRICA
    5.11 TRADE ANALYSIS
           5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                     TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
                     TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
    5.12 TECHNOLOGY ANALYSIS
    5.13 KEY CONFERENCES & EVENTS IN 2022–2023
           TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           5.14.1 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
           5.14.2 REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
    5.15 KEY STAKEHOLDERS & BUYING CRITERIA
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
                     TABLE 11 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
           5.15.2 BUYING CRITERIA
                     FIGURE 26 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
                     TABLE 12 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    5.16 CASE STUDY
           FIGURE 27 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 84)
    6.1 INTRODUCTION
           TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
           TABLE 14 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
    6.2 REAGENTS, KITS, AND CONSUMABLES
           6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH
                     TABLE 15 INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND
                     TABLE 16 KEY INSTRUMENTS AVAILABLE IN MARKET
                     TABLE 17 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.4 SOFTWARE & SERVICES
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE SEGMENT GROWTH
                     TABLE 18 INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. - 91)
    7.1 INTRODUCTION
           TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2020–2027 (USD MILLION)
    7.2 LABORATORY TESTING
           7.2.1 RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                     TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2020–2027 (USD MILLION)
    7.3 POC TESTING
           7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH
                     TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020–2027 (USD MILLION)
           7.3.2 GLOBAL POC TESTING MARKET, BY END USER
                     TABLE 22 GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
                     TABLE 23 GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 24 GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 25 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
           7.3.3 POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT
                     TABLE 26 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION)

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 97)
    8.1 INTRODUCTION
    8.2 PRIMARY NOTES
           8.2.1 KEY INDUSTRY INSIGHTS
                     TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.3 IMMUNODIAGNOSTICS
           8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH
                     TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
           8.3.2 IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE
                     TABLE 29 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
    8.4 PCR
           8.4.1 EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH
                     TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
    8.5 CLINICAL MICROBIOLOGY
           8.5.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE MARKET GROWTH
                     TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020–2027 (USD MILLION)
    8.6 INAAT
           8.6.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
                     TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
    8.7 DNA SEQUENCING & NGS
           8.7.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH
                     TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
    8.8 DNA MICROARRAY
           8.8.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
                     TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2020–2027 (USD MILLION)
    8.9 OTHER TECHNOLOGIES
           TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 106)
    9.1 INTRODUCTION
           TABLE 36 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
    9.2 COVID-19
           9.2.1 OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE
                     TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 38 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (MILLION TESTS)
                     TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020–2027 (USD MILLION)
    9.3 HEPATITIS
           9.3.1 INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH
                     TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (MILLION TESTS)
                     TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020–2027 (USD MILLION)
    9.4 HIV
           9.4.1 HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH
                     TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (MILLION TESTS)
    9.5 HOSPITAL-ACQUIRED INFECTIONS
           9.5.1 RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH
                     TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (MILLION TESTS)
    9.6 MOSQUITO-BORNE DISEASES
           9.6.1 INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH
                     TABLE 47 MAJOR PRODUCTS: DENGUE TESTING
                     TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
    9.7 HPV
           9.7.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
                     TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (MILLION TESTS)
    9.8 CHLAMYDIA TRACHOMATIS
           9.8.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH
                     TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (MILLION TESTS)
    9.9 NEISSERIA GONORRHEA
           9.9.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH
                     TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION, 2020–2027 (USD MILLION)
    9.10 TUBERCULOSIS
           9.10.1 INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH
                     TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (MILLION TESTS)
                     TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2020–2027 (USD MILLION)
    9.11 INFLUENZA
           9.11.1 RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH
                     TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (MILLION TESTS)
                     TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020–2027 (USD MILLION)
    9.12 SYPHILIS
           9.12.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
                     TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020–2027 (USD MILLION)
    9.13 OTHER INFECTIOUS DISEASES
           TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 124)
     10.1 INTRODUCTION
             TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.2 DIAGNOSTIC LABORATORIES
             10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE
                         TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
     10.3 HOSPITALS & CLINICS
             10.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH
                         TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
     10.4 ACADEMIC RESEARCH INSTITUTES
             10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH
                         TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
     10.5 OTHER END USERS
             TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 130)
     11.1 INTRODUCTION
             TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
             TABLE 68 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 69 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 71 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 72 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Increasing prevalence of infectious diseases to drive market growth
                                     TABLE 73 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 74 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 75 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 76 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Focus on affordable tests to drive market growth
                                     TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 78 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 79 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 80 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.3 EUROPE
             TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 84 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing healthcare expenditure to drive market growth
                                     TABLE 86 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 87 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 88 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 89 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth
                                     TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 91 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 92 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 93 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth
                                     TABLE 94 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 95 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 96 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 97 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth
                                     TABLE 98 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 99 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 100 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 101 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Rising geriatric population to drive market growth
                                     TABLE 102 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 103 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 104 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 105 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 106 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 107 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 108 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 109 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 29 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
             TABLE 110 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 111 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 113 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 114 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Growing public access to modern healthcare to drive market growth
                                     TABLE 115 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 116 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 117 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 118 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Universal healthcare reimbursement policy to drive market growth
                                     TABLE 119 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 120 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 121 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 122 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing private & public investments in healthcare system to drive market growth
                                     TABLE 123 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                     TABLE 124 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                     TABLE 125 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                     TABLE 126 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 127 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 128 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 129 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 130 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS
                        TABLE 131 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 132 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 133 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH
                        TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 136 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 137 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 138 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 175)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS
                        TABLE 139 OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
           FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
     12.4 MARKET SHARE ANALYSIS
             12.4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET
                        FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)
                        TABLE 140 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 LIST OF EVALUATED VENDORS
             12.5.2 STARS
             12.5.3 EMERGING LEADERS
             12.5.4 PERVASIVE PLAYERS
             12.5.5 PARTICIPANTS
                        FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
     12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021)
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
     12.7 COMPETITIVE BENCHMARKING
             12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                        FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
                        TABLE 141 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 142 COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 143 COMPANY REGIONAL FOOTPRINT
                        TABLE 144 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     12.8 COMPETITIVE SCENARIO
             12.8.1 PRODUCT LAUNCHES
                        TABLE 145 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
             12.8.2 DEALS
                        TABLE 146 KEY DEALS

13 COMPANY PROFILES (Page No. - 187)
(Business overview, Products offered, Recent Developments, MNM view)* 
     13.1 KEY PLAYERS
             13.1.1 ABBOTT LABORATORIES
                        TABLE 147 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
                        TABLE 148 PRODUCT LAUNCHES & APPROVALS
             13.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 149 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             13.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.4 SIEMENS HEALTHINEERS AG
                        TABLE 151 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                        FIGURE 38 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
             13.1.5 BIOMÉRIEUX SA
                        TABLE 152 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 39 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             13.1.6 DANAHER CORPORATION
                        TABLE 153 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.7 HOLOGIC, INC.
                        TABLE 154 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.8 BECTON, DICKINSON AND COMPANY
                        TABLE 155 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.9 PERKINELMER, INC.
                        TABLE 156 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 43 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
             13.1.10 SEEGENE, INC.
                        TABLE 157 SEEGENE, INC.: BUSINESS OVERVIEW
                        FIGURE 44 SEEGENE, INC.: COMPANY SNAPSHOT (2021)
             13.1.11 QUIDEL CORPORATION
                        TABLE 158 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.12 QIAGEN N.V.
                        TABLE 159 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             13.1.13 DIASORIN S.P.A
                        TABLE 160 DIASORIN S.P.A: BUSINESS OVERVIEW
                        FIGURE 47 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
             13.1.14 BIO-RAD LABORATORIES, INC.
                        TABLE 161 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
             13.1.15 GRIFOLS S.A.
                        TABLE 162 GRIFOLS S.A.: BUSINESS OVERVIEW
                        FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
             13.1.16 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
                        TABLE 163 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
                        FIGURE 50 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
             13.1.17 SYSMEX CORPORATION
                        TABLE 164 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 51 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
     13.2 OTHER PLAYERS
             13.2.1 MERIDIAN BIOSCIENCE
             13.2.2 ORASURE TECHNOLOGIES
             13.2.3 CO-DIAGNOSTICS
             13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
             13.2.5 TRINITY BIOTECH PLC
             13.2.6 GENETIC SIGNATURES LTD.
             13.2.7 EPITOPE DIAGNOSTICS
             13.2.8 TRIVITRON HEALTHCARE
             13.2.9 ELITECHGROUP
             13.2.10 MERIL LIFESCIENCES PVT. LTD.
             13.2.11 INBIOS INTERNATIONAL
             13.2.12 UNIOGEN OY
             13.2.13 VELA DIAGNOSTICS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 287)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.  After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

Infectious Disease Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the infectious disease diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the infectious disease diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Infectious Disease Diagnostics Market Size: Top-Down Approach

Infectious Disease Diagnostics Market Top-Down Approach, and Share

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global infectious disease diagnostics market by product & service, type of testing, technology, disease type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the infectious disease diagnostics market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Infectious Disease Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Company profiles of 30 players operating in the infectious disease diagnostics market
Infectious Disease Diagnostics Market Size,  Share & Growth Report
Report Code
MD 3088
Published ON
Jun, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status